A First in Man Trial for Patients With Cancer


About this study

The primary objective of this study is to determine the safe and tolerable dose level of OPB-111077 for patients with advanced cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Pathologically and/or cytologically confirmed advanced malignancy that is refractory to standard therapy or for which there are no standard treatment options available
  • For oral or intravenous anticancer therapies, at least 4 weeks or 5 half-lives, whichever is shorter, need to have elapsed since the last dose
  • Recovery from adverse effects of prior therapy at time of enrollment to o ≤ Grade 1 (excluding alopecia)
  • Agreement to forego any other chemotherapy, immunotherapy, radiotherapy, or investigational drug while enrolled on this trial except hormonal therapy for prostate cancer or radiotherapy for symptomatic bone metastases known to be present at Screening
  • Male or female subjects aged ≥ 18 years
  • ECOG performance status ≤ 2
  • Adequate organ function
  • Life expectancy of ≥ 3 months following trial entry
  • For women of childbearing potential, a negative serum pregnancy test result at Screening
  • For women of childbearing potential or men whose sexual partners are women of childbearing potential, agreement to use 2 methods of adequate contraception prior to trial entry, for the duration of the trial, and for 90 days after the last dose of trial medication
  • Signed and dated IRB-approved informed consent prior to any performance of protocol-specific screening procedures

Exclusion Criteria:

  • Uncontrolled concurrent illness, including but not limited to: ongoing or active infection; uncontrolled heart, liver, kidney, or endocrine disorder
  • Altered mental status, psychiatric illness, or social situation that would limit compliance with trial requirements and/or obscure trial results
  • Immunocompromised state
  • Known or evidence of chronic viral hepatitis (hepatitis B or C virus)
  • Untreated or symptomatic brain metastasis, or subjects with leptomeningeal disease
  • Inability to swallow oral meds or gastrointestinal disorder that might interfere with absorption of oral drugs
  • Major surgery within 28 days of first receipt of trial drug
  • Nursing or pregnant women
  • ≥ Grade 1 neuropathy with pain or > Grade 2 neuropathy without pain (subjects with neuropathy caused by a previous regimen that is recovered to ≤ Grade 2 and stable without pain may be included)
  • Food-effect sub-study (Part B) only: Pathologies or medical histories that might impair absorption and elimination.
  • PET scan sub-study (Part C) only: Uncontrollable blood glucose or intolerance to PET scan procedures.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thomas Witzig, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Mayo Clinic Footer